FIELD: chemistry.
SUBSTANCE: invention relates to specific derivatives of pyrrolo[3,2-b]pyridine. Invention also relates to a heterocyclic compound of formula (IA), where R1 is halogen, cyano, C1-4alkyl or C1-4alkoxy; R2 is hydrogen; p is 1 or 2, and each R4 are independently selected from halogen, C1-4alkyl, C1-4alkoxy, C1-4haloalkyl and C1-4 haloalkoxy; to a heterocyclic compound of formula (IB), where R1 is halogen, C1-4alkyl or C1-4alkoxy; R2 is hydrogen; R4a is hydrogen or halogen; R4b is hydrogen, halogen, C1-4alkyl, C1-4alkoxy, C1-4haloalkyl or C1-4haloalkoxy; R4c is hydrogen, halogen, C1-4alkyl, C1-4alkoxy or C1-4haloalkyl; and R4d is hydrogen or halogen, where at least one of R4a, R4b, R4c and R4d are not hydrogen, and not more than two of R4a, R4b, R4c and R4d are hydrogen; to a method for symptomatic treatment of cognitive disorders in dementia of Alzheimer's type (AD) and dementia with Levy bodies (DLB); to a pharmaceutical composition based on said compounds. (IA)
(IB).
EFFECT: technical result is obtaining novel heterocyclic compounds which are muscarine acetylcholine receptor (mAChR) M1 modulators.
20 cl, 5 tbl
Title | Year | Author | Number |
---|---|---|---|
HETEROCYCLIC COMPOUND | 2018 |
|
RU2791533C2 |
ARYL-SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | 2010 |
|
RU2575168C2 |
IMPROVED APELIN RECEPTOR AGONISTS (APJ) AND THEIR USE | 2016 |
|
RU2766148C1 |
URIDINE-5-DIPHOSPHATE (UDP) GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF THEIR USE | 2019 |
|
RU2810928C2 |
TREATMENT METHOD | 2012 |
|
RU2621148C2 |
TRANSGLUTAMINASE 2 (TG2) INHIBITORS | 2019 |
|
RU2781370C2 |
FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | 2014 |
|
RU2671979C2 |
AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | 2019 |
|
RU2801140C2 |
BETA-LACTAMASE INHIBITORS AND THEIR USE | 2018 |
|
RU2815314C2 |
BENZOTHIAZOLE COMPOUNDS AND METHODS FOR THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 2018 |
|
RU2778370C2 |
Authors
Dates
2019-05-23—Published
2014-09-30—Filed